Armour Thyroid Switching Protocols: Converting To and From Other Thyroid Drugs

How Armour Thyroid Works: Mechanism and Composition

Armour Thyroid is a porcine-derived preparation containing both thyroxine (T4) and triiodothyronine (T3) in a fixed ratio. Each 60 mg tablet (1 grain) delivers approximately 38 mcg of T4 and 9 mcg of T3. [1] The T3 fraction is what distinguishes NDT from levothyroxine monotherapy and drives most of the clinical differences between the two preparations.

The T4-to-T3 Conversion Pathway

In healthy thyroid physiology, roughly 80% of circulating T3 is produced by peripheral deiodination of T4 by type 1 and type 2 deiodinases in tissues including the liver, kidney, and skeletal muscle. [2] Patients with hypothyroidism who rely solely on exogenous T4 depend entirely on that deiodinase system to generate T3. About 15 to 20% of people with hypothyroidism carry polymorphisms in the type 2 deiodinase gene (DIO2), which may impair conversion efficiency and partly explain persistent symptoms on levothyroxine monotherapy. [3]

Why the Fixed T4:T3 Ratio Matters Clinically

The T4:T3 ratio in Armour Thyroid is approximately 4.2:1 by weight and roughly 4:1 in molar activity terms. The normal human thyroid secretes T4 and T3 in a molar ratio closer to 14:1, [4] meaning NDT delivers a proportionally higher T3 load than the healthy gland does. This produces a predictable transient post-dose T3 spike. Serum T3 peaks 2 to 4 hours after ingestion, then falls toward baseline by 8 hours. [5] That pharmacokinetic profile is relevant when interpreting lab results: a T3 drawn within 4 hours of a morning dose will overestimate the steady-state T3 level.

Receptor-Level Action

Both T4 and T3 bind thyroid hormone receptors (TR-alpha and TR-beta) in the cell nucleus, regulating gene transcription across metabolic, cardiovascular, and neurological pathways. [6] T3 has roughly 10 to 15 times greater binding affinity for thyroid hormone receptors than T4 does, so the T3 content of NDT drives a disproportionate share of its biological effect. [6] This higher receptor activity is the pharmacological basis for why some patients report faster symptomatic response after switching to NDT.

Clinical Evidence Comparing NDT and Levothyroxine

Hoang et al. 2013: The Primary Comparative Trial

The most frequently cited head-to-head study remains Hoang et al. (J Clin Endocrinol Metab, 2013), a randomized crossover trial in 70 adults with hypothyroidism. [7] Participants spent 16 weeks on NDT and 16 weeks on levothyroxine in random order. TSH, free T4, and free T3 were similar between arms. Body weight was slightly but statistically lower on NDT (mean difference approximately 0.4 kg, P<0.05). Patient preference was notable: 48.6% preferred NDT, 18.6% preferred levothyroxine, and 32.9% had no preference. [7]

What the Trial Did Not Measure

The Hoang study was 16 weeks per arm, which is long enough to assess symptom burden but not long enough to capture long-term cardiovascular endpoints. NDT's higher T3 exposure raises theoretical concern for atrial fibrillation and bone loss. A 2017 population-based Danish cohort study (N=40,856) found no significant increase in atrial fibrillation incidence among NDT users compared with levothyroxine users after adjusting for confounders, [8] though the absolute number of NDT-treated patients was small relative to the levothyroxine cohort.

Guideline Positions

The American Thyroid Association 2012 guidelines state that "there is currently insufficient evidence to recommend the routine use of combination T4/T3 therapy" but acknowledge that "some patients may benefit." [9] The Endocrine Society's 2014 clinical practice guideline on hypothyroidism in adults similarly notes that most patients are adequately managed on levothyroxine, while leaving room for combination therapy in patients with persistent symptoms. [10] Neither guideline prohibits NDT, and both acknowledge the gap in long-term comparative data.

Switching From Levothyroxine to Armour Thyroid

Dose Conversion and Starting Point

The standard conversion ratio used in clinical practice is 60 mg (1 grain) of Armour Thyroid for every 100 mcg of levothyroxine. [1] This ratio is empirically derived and accounts for the bioequivalent T4 contribution plus the T3 that NDT provides in place of the T4 that would otherwise be peripherally converted. In practice, many prescribers start at a slightly lower NDT dose, then titrate up, particularly in patients over 60 or those with any history of cardiac arrhythmia.

A sample conversion table:

| Levothyroxine Dose | Starting NDT Dose | Approximate Grain | |--------------------|-------------------|-------------------| | 50 mcg | 30 mg | 0.5 grain | | 75 mcg | 45 mg | 0.75 grain | | 100 mcg | 60 mg | 1 grain | | 125 mcg | 75 mg | 1.25 grain | | 150 mcg | 90 mg | 1.5 grain | | 200 mcg | 120 mg | 2 grain |

Titration Timeline

Stop levothyroxine on day 1 and begin NDT the same morning at the calculated starting dose. Do not taper or overlap; the half-life of T4 is approximately 7 days, so there is a built-in pharmacokinetic buffer. [11] Recheck TSH, free T4, and free T3 at 6 to 8 weeks. If TSH remains above 2.5 mIU/L and the patient still has symptoms, increase by 15 to 30 mg (0.25 to 0.5 grain) and recheck in another 6 weeks. Most patients stabilize within 3 dose adjustments over 3 to 5 months.

Lab Interpretation After Switching

Free T4 will typically run lower on NDT than on equivalent levothyroxine doses because NDT delivers less T4 per unit of thyroid activity. [7] A low-normal free T4 alongside a mid-range TSH and a normal free T3 is an expected and acceptable finding on NDT, not a sign of under-replacement. Over-relying on free T4 as the primary endpoint after switching leads to unnecessary dose escalation.

Switching From Armour Thyroid to Levothyroxine

Why Patients Switch Back

Some patients switch back to levothyroxine because of palpitations related to T3 peaks, unavailability during supply shortages, insurance coverage issues, or a prescriber preference for the more extensively studied monotherapy. Palpitation-related switching is more common in patients whose free T3 runs in the upper quartile of the reference range on NDT. [12]

Reverse Conversion Protocol

Apply the same 100-mcg-per-60-mg ratio in reverse. A patient on 90 mg (1.5 grains) of NDT would start levothyroxine at approximately 150 mcg. Stop NDT on day 1; start levothyroxine that same morning. Because levothyroxine has a longer time to steady state (4 to 6 weeks), the first lab check should occur at 6 to 8 weeks. [11]

Managing the T3 Drop

The first 1 to 3 weeks after switching away from NDT often produce transient fatigue, brain fog, or constipation as the circulating T3 pool falls and the levothyroxine-driven peripheral conversion catches up. Patients should be counseled that this window is expected and not a sign that levothyroxine is "not working." Symptoms that persist beyond week 6 warrant a free T3 check; if free T3 is below mid-range, adding low-dose liothyronine (typically 5 mcg once daily) may be considered. [10]

Switching Between NDT and Combination T4/T3 Therapy

NDT vs. Levothyroxine Plus Liothyronine

Some clinicians manage patients on levothyroxine combined with synthetic liothyronine (Cytomel or generic T3) rather than NDT. The pharmacological content is similar in principle, but the ratio is not fixed: prescribers can adjust T4 and T3 doses independently. NDT delivers a T4:T3 ratio of about 4.2:1 by weight, whereas a typical combination therapy prescription might use a ratio of 10:1 or even 20:1 in favor of T4 to avoid supratherapeutic T3 peaks. [13]

Converting from Combination T4/T3 to NDT

Add the total T4 equivalent first. Calculate the T3 component's levothyroxine equivalent using the standard 1 mcg liothyronine = 3 mcg levothyroxine approximation, [14] then add to the actual levothyroxine dose. Convert that total levothyroxine equivalent to NDT at the 100-mcg-per-60-mg ratio. For example, a patient on levothyroxine 100 mcg plus liothyronine 5 mcg daily would have a T4 equivalent of approximately 115 mcg, converting to roughly 69 mg NDT (round to 60 or 75 mg and titrate).

Converting from NDT to Combination T4/T3

Calculate the T4 content of the NDT dose (38 mcg per 60 mg grain) as the levothyroxine starting dose. Then add back only a fraction of the T3 content, typically 5 to 10 mcg of liothyronine daily, because synthetic T3 has more predictable pharmacokinetics than the T3 in NDT. [5] Recheck labs at 6 weeks.

Switching From Other NDT Brands to Armour Thyroid

Brand Differences That Matter

Several NDT products are available in the United States: Armour Thyroid (AbbVie), Nature-Throid and WP Thyroid (both from RLC Labs), and NP Thyroid (Acella Pharmaceuticals). [1] All are standardized to USP specification: each grain contains not less than 38 mcg T4 and not less than 9 mcg T3. [15] Despite nominal equivalence, excipients differ across brands. Nature-Throid and WP Thyroid use fewer fillers, which may affect absorption rate in patients with GI hypersensitivity or celiac disease. [16]

Practical Switching Advice Between NDT Brands

Switch brand-to-brand at the same dose in milligrams. Do not adjust the dose at the time of brand switch; wait 6 weeks and recheck TSH, free T4, and free T3 before deciding whether to titrate. Patients who switch from Armour Thyroid to NP Thyroid or vice versa occasionally report symptom shifts even at the same milligram dose, likely reflecting inter-product variation in T3 bioavailability. [16]

Special Populations and Contraindications for Switching

Cardiovascular Disease and Arrhythmia Risk

Patients with known atrial fibrillation, recent myocardial infarction, or unstable angina should not be switched to NDT without cardiology input. The T3 surge after each NDT dose raises heart rate and may increase adrenergic burden. [6] A 2019 analysis of thyroid hormone use in heart failure patients found that supraphysiologic T3 exposure correlated with higher rates of ventricular arrhythmia in structurally abnormal hearts. [17] In these patients, levothyroxine monotherapy remains the safer option.

Pregnancy

The American College of Obstetricians and Gynecologists and the Endocrine Society both recommend levothyroxine as the standard thyroid replacement in pregnancy because NDT's variable T3 content makes TSH targets harder to maintain. [18] TSH targets during pregnancy are trimester-specific: below 2.5 mIU/L in the first trimester and below 3.0 mIU/L in the second and third trimesters per the 2017 American Thyroid Association guidelines on thyroid disease in pregnancy. [19] Women who conceive on NDT should discuss converting to levothyroxine with their prescriber at the earliest possible prenatal visit.

Adrenal Insufficiency

Undiagnosed or undertreated adrenal insufficiency is a relative contraindication to any increase in thyroid hormone, including switching to a more potent preparation like NDT. Increased metabolic clearance of cortisol under higher thyroid hormone levels can precipitate adrenal crisis. [20] Morning cortisol or ACTH stimulation testing should precede NDT initiation in patients with signs of adrenal fatigue.

Optimizing Absorption and Drug Interactions

Timing and Food Effects

Armour Thyroid, like levothyroxine, should be taken on an empty stomach 30 to 60 minutes before the first meal. Coffee consumed within 30 minutes of ingestion reduces levothyroxine absorption by roughly 36% in controlled studies, [21] and the same interaction likely applies to NDT. Moving to bedtime dosing is an alternative that may improve compliance and, in some data, produces modestly better TSH suppression. [22]

Key Interactions

Calcium carbonate, ferrous sulfate, and aluminum-containing antacids all reduce thyroid hormone absorption significantly. Cholestyramine and colestipol bind thyroid hormones in the GI tract and should be separated by at least 4 hours. [1] Proton pump inhibitors reduce gastric acid and may decrease absorption of NDT, though the magnitude of this effect is smaller than with calcium and iron. [23] Rifampin, carbamazepine, and phenytoin accelerate hepatic T4 and T3 clearance via CYP3A4 induction and may require NDT dose increases of 20 to 40%. [1]

Monitoring Protocol After Any Switch

Recommended Lab Panel

After any thyroid medication switch, the minimum lab panel is TSH plus free T4 plus free T3. Relying on TSH alone is insufficient after switching to NDT because the T3-rich preparation can suppress TSH into the normal or low-normal range while free T3 remains within range. A TSH-only approach would misclassify a well-replaced NDT patient as hyperthyroid. [7]

Timing of the Blood Draw

Draw labs in the morning, before the day's dose is taken, and at least 4 hours after the previous day's last dose if split dosing is used. This captures the trough T3 level rather than the post-dose peak. [5] TSH has the slowest response time of the three tests; it reflects the average thyroid hormone exposure over the prior 4 to 6 weeks, so a single early TSH check does not accurately reflect the new steady state.

Long-Term Surveillance

After dose stabilization, annual thyroid panels are appropriate for most patients. Bone density screening (DXA) should follow standard age and sex guidelines; TSH persistently below 0.5 mIU/L on any thyroid hormone preparation is associated with reduced bone mineral density and should prompt dose re-evaluation. [24] A 2015 meta-analysis (N=4,476 across 13 studies) found that subclinical hyperthyroidism defined by TSH below 0.1 mIU/L was associated with a hazard ratio of 1.41 for hip fracture (95% CI 1.18 to 1.68). [24]